Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Press Releases – Page 2 – Global Alzheimer's Platform Foundation
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease | Nature
Aduhelm (aducanumab) Q+A - Penn Memory Center
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
The Future of Alzheimer's Treatment? Approval of Aduhelm & Other Anti-Amyloid Antibodies – Montgomery County Medical Society
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
Early Access Programs | Biogen
FDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questions - CBS News
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen
FDA approves much-debated Alzheimer's drug panned by experts | AP News
Biogen is ready to roll on lecanemab production, CFO says
With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
Biogen readies Alzheimer's hopeful aducanumab for U.S. launch as stateside sales plummet | Fierce Pharma
Medicare Finalizes Limits on Aducanumab Coverage | MedPage Today
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YOZVWDX35VKEVCOQV4LDNO3ZTQ.jpg "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day\" for patients | Reuters")
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
FDA approves much-debated Alzheimer's drug panned by experts | AP News
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
